There are a number of people who, unlike myself, knew and worked with Alexander Haddow; and many more whose work in the clinic and laboratory is built on the early foundations he laid as a pioneer of chemotherapy and hormone therapy for cancer before and immediately after the war. In these circumstances it would be inappropriate for me to try to emunerate or even to summarize scientific achievements which are already well known.
Instead, drawing upon the recollections of Professor Peter Alexander, I will try in two brief anecdotes to recapture aspects of a rich character who was as formidable with officialdom as he was kind to his colleagues and junior associates. Peter Alexander recalls an incident in the early 1950s when he accompanied Alex to the Ministry of Health, at that time in Savile Row, to see Sir John Charles the then CMO. On the way up in the lift there was a poster acclaiming the message 'Help us to keep our secrets secret'. Haddow removed the poster and put it on the desk of the CMO. 'A Department of Health has no business to have any secrets' said he! Another occasion that Peter Alexander recollects vividly was when, at a discussion at the Finance Committee of the Chester Beattie, Haddow made the sharp rejoinder -'you don't seem to appreciate the division of functions in this Committee, your responsibility is to find the money, mine to spent it!'
A little less than two years ago on 25 February 1987 the British Government made a remarkable and, some would add, a courageous decision. It was to set up a system, financed by public funds, which would ensure that by 1990 each and every one of some five million women in the UK aged 50-64 would be offered screening for breast cancer by mammography every three years, the hoped for objective being to reduce the number of deaths from breast cancer in this age group by about 30%.
But there is a ghost at this particular feast! In 1966 a previous government made a similar decision about another type of cancer screening -screening for cervical cancer. Twenty years later in spite of the completion of tens of millions of smears, and of the expenditure of many tens of millions of pounds we have precious little to show for it. There has been only a small reduction in the mortality from cervical cancer and in spite of our efforts over 22 years about half of the cases of cervical cancer presenting for treatment are in women who have never been screened.
The problem of breast cancer in Britain Breast cancer is by far the most common form of cancer amongst women in Britain. In recent years nearly 25 000 cases have been diagnosed each year and about 15 000 women have died of it. Incidence and mortality continue to increase. In international terms, there is at least a superficial resemblance to the pattern of mortality from coronary heart disease in men, because the countries of the United Kingdom are at the top of the league. There is no doubt that breast cancer presents us with a massive health problem in this country.
But there are two further points that have to be made in this context. The first is that although we know much about the aetiology of breast cancer we do not yet know how to prevent it. The second is that treatment is far from satisfactory (although improving). About two-thirds of the people affected by breast cancer are likely to die of it sooner or later. Furthermore the stage at which treatment is carried out is the most important factor affecting outcome. And to emphasize the point, it is known that the smallest cancers, those less than 1 cm in diameter, are less likely to have metastasized to lymph nodes or to distant sites than larger tumours. Unfortunately in the UK there is tendency for women to present with large and advanced tumours.
It is these points taken together (ie high incidence of breast cancer, no known prevention and dependence of successful treatment on early diagnosis) which have focused attention in countries where the disease is common, on methods of screening which it is hoped will enable treatment to be offered at an earlier stage than is currently the case.
One other point -although many risk factors are known in relation to the aetiology of breast cancer such as early menarche, late childbearing, family history, and ionising radiation, only one, age, is suitable to use in screening programmes to sort those for whom screening is advised from those for whom it is not advised.
The events which led up to the 1987 decision At the time of the decision in 1985 to set up the Forrest Committee the results oftwo large randomized controlled studies had been published, the Health Insurance Plan of Greater New York (HIP) and the Swedish Two Counties Programme. In both, the results were consistent with the view that mammography detected cancers early, such that treatment altered the natural history of the disease beneficially.
Without going into details both studies showed a reduction in mortality of about 30% in women who had accepted screening. This benefit was largely limited to women over 50. Although the results of the UK Trial of Early Detection of Breast Cancer (TEDBC) had not been published, it was clear that in Edinburgh and Guildford -ifthese are representative of Britain -reasonable compliance (60-70% of the women attended for the first screen) occurred, and adequate compliance is a prerequisite for a successful screening programme. In addition two case-control studies in the Netherlands, had shown in 1984 a reduction of mortality of between 30-50% in the screened as opposed to the unscreened women.
Thus in March 1985 thanks to the fact that we had received a pre-publication copy of the Swedish Two Counties Study we were able to advise the Minister that in our opinion the moment had come to reappraise our policy before it appeared in the Lancet on 13 April. He was therefore able to announce the setting-up of the Forrest Committee on the day the article appeared. On this occasion the Department of Health did not sit on its hands. With great speed, economy of words and clarity of thought, Patrick Forrest and his colleagues prescribed the remedy. The remedy was that there should be a change in UK policy on the provision of mammographic facilities and the screening of symptomless women for breast cancer.
In other words a National Breast Screening Programme should be set up: (a) to provide for a mass population-based screening service for all women aged 50-64 based on single-view high quality mammography at three year intervals; (b) to provide adequate diagnostic back-up services; and (c) to build in parallel a research and evaluation programme. The report included an economic appraisal which showed that, in terms of quality-adjusted life years gained, the cost would be £3000 per year, ie more than a hip replacement, equivalent to a kidney transplantation and less than a heart transplant.
What is involved
Forrest described four stages in the screening process: Stage 1: The basic screen at the end of which a decision is made as to whether the mammogram is normal or not normal Stage 2: The assessment at the end of which a decision is made as to whether a biopsy is required to prove or disprove cancer, or whether there is a need to keep the woman under observation or whether the breast is in fact normal Stage 3: The biopsy to determine if the lesion is benign or malignant Stage 4: Treatment for those found to have cancer. The numbers give some cause for concern. Ten per cent of those screened will have reason to feel anxious as their mammograms will have an abnormality requiring further investigation at the assessment stage. However, of these only 5% will have cancer. In other words as far as the mammograms are concerned, 19 out of 20 will turn out on further assessment to have been false positive tests. Speed in clearing-up the uncertainty is therefore essential. Mammography also fails to detect some breast cancers: about two or three of every 10 women who have breast cancer may be missed by screening at a three-yearly interval.
The structure of the programme For each population of half a million there will be: a screening office which is the administrative centre and which will hold the details of the eligible women in a computerized form; one or more screening units -static or mobile staffed by radiographers; and in each region there will be one or more assessment centres with special back-up services including ultrasonography, radiology, cytology and histopathology.
It is intended that the system should be organized as part of primary care in which the woman's GP, with nursing support, has an essential role in inviting the women to come forward, and counselling them at every stage as necessary. Research is developing protocols for studies to look at screening in the 40-49 year olds, at the interval between screens and at the question of the number of the mammographic views. .The programme has been publicised in a number of ways: Dr Muir Gray has started a regular newsheet 'Network' for those health-care professionals involved in the programme; the Health Education Authority has developed a leaflet that is intended to accompany the letter inviting a woman for screening; and the Cancer Research Campaign has prepared an Information Pack and Booklet about the programme for the Primary Care Team.
Since embarking on the programme the first results of the UK Trials of the Early Detection of Breast Cancer have been published. Although in the women offered screening these didn't show a statistically significant reduction in mortality, the results are in the same direction as the HIP and the Swedish Two Counties studies. The results serve to heighten the importance of a first-class quality service and of good compliance by the women offered screening for the success of the screening programme.
Conclusions
This project, so far as I know unparalleled anywhere in the world where a comprehensive programme of screening covering the whole of a defined group of women on a national basis in a large country, is being brought in to being with the objective of-reducing the mortality from breast cancer.
The project rests on a solid bedrock of scientific fact which, in my opinion, shows beyond doubt that it is possible, subject to quality and compliance, substantially to reduce mortality from this disease.
There is a built-in system of evaluation and quality control, together' with a research programme to cast light on those areas such as interval between screens, number of mammographic views, and the screening of the 40-49 year olds.
An appropriate administrative structure and training programme have been set up.
Government, Forrest and other advisory committees, the medical profession and the NHS have all acted with most commendable speed since the publication of Two Counties Study in April 1985 -and we are still more or less on schedule to have national cover in 1990.
For all these reasons we are much more likely to succeed quickly in reducing mortality than were the attempts to do so for cervical cancer in 1966.
Nevertheless to achieve good results at a reasonable cost, it will be necessary to gain commitment not only from the people of many different skills who will have to work at a very high level of quality of diagnosis and treatment, but also from the women of this country without whose confidence in the programme, we cannot hope to obtain the necessary level of compliance. High quality and high compliance are the keys to success -and they depend on knowledge, skill, commitment and enthusiasm. We have made a good start on a great adventure. Alex, I suspect would approve.
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